The University of Michigan Medicine has developed an AI-based diagnostic screening tool to detect genetic mutations in brain tumors in less than 90 seconds.
DeepGlioma tool can improve brain tumor diagnosis and treatment speed and accuracy, increasing the chances of defining treatments and predicting patient prognosis.
The study focused specifically on diffuse gliomas, a common form of brain tumor that arises from glial cells.
- Diffuse gliomas are characterized by their ability to surround brain tissue using diffuse infiltration.
- The researchers achieved an average molecular genetic classification accuracy of 93.2% and identified the correct diffuse glioma molecular subgroup with 91.2% accuracy within two minutes while in the operating room.
- This new AI tool could enable medical care providers to accurately identify the type of brain tumor and determine the most effective treatment, which could significantly impact patient outcomes.
- Brain and nervous system cancers are the 10th leading cause of death for men and women, and brain tumors are more common in children and older adults.
Zoom Out:
- This new AI tool holds great promise for rethinking clinical trial design and bringing new therapies to patients.
